111 related articles for article (PubMed ID: 8558719)
1. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer.
Werthman PE; Drazan KE; Rosenthal JT; Khalili R; Shaked A
J Urol; 1996 Feb; 155(2):753-6. PubMed ID: 8558719
[TBL] [Abstract][Full Text] [Related]
2. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
Kuball J; Wen SF; Leissner J; Atkins D; Meinhardt P; Quijano E; Engler H; Hutchins B; Maneval DC; Grace MJ; Fritz MA; Störkel S; Thüroff JW; Huber C; Schuler M
J Clin Oncol; 2002 Feb; 20(4):957-65. PubMed ID: 11844817
[TBL] [Abstract][Full Text] [Related]
3. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer.
Sutton MA; Freund CT; Berkman SA; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Lerner SP
Mol Ther; 2000 Sep; 2(3):211-7. PubMed ID: 10985951
[TBL] [Abstract][Full Text] [Related]
4. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
5. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
6. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
8. Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector.
Shimizu H; Akasaka S; Suzuki S; Akimoto M; Shimada T
Urology; 2001 Mar; 57(3):579-84. PubMed ID: 11248651
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
10. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection.
Drazan KE; Shen XD; Csete ME; Zhang WW; Roth JA; Busuttil RW; Shaked A
Surgery; 1994 Aug; 116(2):197-203; discussion 203-4. PubMed ID: 8047986
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated suicide gene therapy for experimental bladder cancer.
Sutton MA; Berkman SA; Chen SH; Block A; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Woo SL; Lerner SP
Urology; 1997 Feb; 49(2):173-80. PubMed ID: 9037277
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated gene transfer to bladder in vivo.
Morris BD; Drazan KE; Csete ME; Werthman PE; Van Bree MP; Rosenthal JT; Shaked A
J Urol; 1994 Aug; 152(2 Pt 1):506-9. PubMed ID: 8015103
[TBL] [Abstract][Full Text] [Related]
13. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
Shiau AL; Lin CY; Tzai TS; Wu CL
Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
[TBL] [Abstract][Full Text] [Related]
14. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
15. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin.
Pagliaro LC; Keyhani A; Liu B; Perrotte P; Wilson D; Dinney CP
Urol Oncol; 2003; 21(6):456-62. PubMed ID: 14693272
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer.
Miyake H; Hara I; Gohji K; Yamanaka K; Arakawa S; Kamidono S
Anticancer Res; 1998; 18(4C):3087-92. PubMed ID: 9713515
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
[TBL] [Abstract][Full Text] [Related]
19. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.
Loskog A; Ninalga C; Hedlund T; Alimohammadi M; Malmström PU; Tötterman TH
Lab Anim; 2005 Oct; 39(4):384-93. PubMed ID: 16197705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
